Vimarsana
Biggest News Aggregation in the World

Page 5 - Patrick Lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Lu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Lu Today - Breaking & Trending Today

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma - Vimarsana News

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Published: August 29, 2022

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Source: prnewswire.com
Related Topics:
United StatesNigel YipMark CorbaeBunny LeeMichael MolyneauxPatrick LuChinese National Medical Products AdministrationSirnaomics LtdDrug AdministrationPrnewswire Sirnaomics LtdExecutive DirectorChief Medical OfficerIncidence EstimateNonmelanoma Skin CancerKeratinocyte CarcinomasOrphan Drug DesignationFinancial OfficerMedia ContactSirnaomics Ltd
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases - Vimarsana News

Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

Published: August 26, 2022

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Source: prnewswire.com
Related Topics:
United StatesNigel YipBunny LeeDmitry SamarskyAlexis FeinbergPatrick LuSirnaomics LtdCompany Or SirnaomicsSirnaomics Chief Technology OfficerExecutive DirectorAdv Clin Exp MedTechnology OfficerFinancial OfficerMedia ContactSirnaomics Ltd
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ - Vimarsana News

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ

Published: August 18, 2022

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Source: prnewswire.com
Related Topics:
United StatesNigel YipBunny LeeAlexis FeinbergMichael MolyneauxPatrick LuChinese National Medical Products AdministrationSirnaomics LtdDrug AdministrationPrnewswire Sirnaomics LtdCompany Or SirnaomicsExecutive DirectorChief Medical OfficerOrphan Drug DesignationFinancial OfficerMedia ContactSirnaomics Ltd
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics - Vimarsana News

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

Published: August 16, 2022

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Source: prnewswire.com
Related Topics:
United StatesDavidm EvansNigel YipBunny LeeDavid EvansAlexis FeinbergSirnaomic GalnacPatrick LuSirnaomics LtdPrnewswire Sirnaomics LtdCompany Or SirnaomicsEndosome EscapePeptide Docking VehicleExecutive DirectorPolypeptide NanoparticleChief Scientific OfficerFinancial OfficerMedia ContactSirnaomics LtdHealth Care Amp Hospitals Banking Amp Financial ServicesBiotechnology Medical Pharmaceuticals Pharmaceuticals Clinical Trials Amp Medical Discoveries
Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment - Vimarsana News

Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

Published: July 26, 2022

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Source: prnewswire.com
Related Topics:
United StatesNigel YipBunny LeeAlexis FeinbergMichael MolyneauxSteven LongPatrick LuDevelopment OfficerLysine CoSirnaomics LtdTaiwan Ministry Of HealthPrnewswire Sirnaomics LtdCompany Or SirnaomicsTaiwan MinistryInvestigational New DrugExecutive DirectorChief DevelopmentHistidine Lysine Co PolymerChief Medical OfficerFinancial OfficerMedia ContactSirnaomics Ltd